Early liver cancer: rare lung disease of new drug "lik"
Last Update: 2020-06-19
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Laboratory for advanced medicine (LAM), which focuses on early cancer screening with innovative technologies, announced that FDA has issued a breakthrough medical device certification for its liver cancer screening testThis early screening technique can detect stage I HCC, with 95% sensitivity and 97.5% specificity< br / > unlike liquid biopsies, which focus on sequence change (base replacement, insertion and deletion, copy number change and rearrangement) of human genome, liquid biopsies (ivygene) developed by Lam company can detect cancer and its location by distinguishing the methylation patterns of different cancersMethylation is a regulation of gene expressionIn tumor cells, demethylation of genes related to tumor rapid growth and methylation of tumor suppressor genes often occur, which turn on and off different oncogenes and tumor suppressor genes respectivelyLam identified 23 different cancer methylation patterns by analyzing more than 100000 blood samples from patientsIn addition, methylation often occurs in the early stages of cancerSo we can find the trace of cancer in the very early stage< br / > the award of this breakthrough medical device certification is based on the positive results of the climb testThe climb trial was conducted in cirrhotic patients who underwent routine ultrasound screening for HCC every six months, while blood was drawn for fluid biopsyThe sensitivity of early screening to stage I to IV HCC is between 89% and 100%, and it can distinguish benign and malignant tumors, reaching the overall specificity of 97.5%< br / > sniper RSV infection! Janssen, a subsidiary of Johnson & Johnson, announced that the U.SFDA has granted the breakthrough therapy of vaccine under development to prevent severe respiratory diseases caused by respiratory syncytial virus (RSV) in the elderly aged 60 and overThis breakthrough therapy represents an important breakthrough in the prevention of RSV infection< br / > Janssen's RSV prophylactic vaccine is part of the vaccine portfolio it is developing, which is aimed at areas in the world that have not yet met the highest demandThis RSV preventive vaccine under development, using the unique characteristics of the adenovirus vector platform of Janssen company, packages the transgenic expression of RSV fusion protein in the adenovirus vector< br / > the confirmation of the breakthrough therapy is based on the clinical data of RSV vaccine of Janssen company Compared with the existing standard nursing, the vaccine shows a clinically significant improvement At present, RSV vaccine is in the stage of 2B concept validation research, which mainly studies the safety and effectiveness of RSV vaccine in the elderly aged 65 and above < br / > US $950 million! Vertex "targets" cell therapy for type 1 diabetes < br / > vertex pharmaceuticals announced a definitive agreement to acquire bioma therapeutics for $950 million in cash, which is developing the world's leading stem cell-derived human islets as a potential cure for type 1 diabetes Semma is developing a differential treatment for type 1 diabetes, and has made two major scientific advances: in animal models, it can produce a large number of functional human pancreatic β cells that can restore insulin secretion and improve hypoglycemia, and a new device that can wrap and protect these cells from the attack of the immune system, which can be implanted for a long time, There is no need for sustained immunosuppressive therapy < br / > The company is committed to transforming Dr Melton's research results in the laboratory, using stem cells to cultivate billions of functional, insulin producing β cells Preliminary preclinical studies in diabetic animal models have shown that blood glucose levels can be controlled by transplanting these cells into the liver This breakthrough technology has been exclusively licensed to semma for the development of cell-based diabetes therapy < br / > reduce the risk by 86%! Gene tech, a subsidiary of Roche, announced that its new anti influenza drug xofluza (baloxavir marboxil) has achieved positive results in the phase 3 clinical research of influenza prevention Baloxavir marboxil reduced the risk of influenza by 86% after exposure < br / > baloxavir marboxil is a "first in class" single dose oral drug It can inhibit the replication of influenza virus by inhibiting cap dependent endonuclease The mechanism of existing anti influenza drugs is to target neuraminidase to prevent the spread of the virus in vivo Compared with these drugs, baloxavir marboxil targets the earlier stage of virus replication cycle, and it can be effective against influenza viruses that have been resistant to oseltamivir Currently, baloxavir marboxil has been approved in several different countries for the treatment of influenza A and B in children, adolescents and adults, and in the United States for the treatment of acute and simple influenza in people aged 12 years and over In addition, a supplementary new drug application (SNDA) of baloxavir marboxil for the treatment of patients at high risk of influenza complications is also under review by the FDA and is expected to be replied by November 4, 2019 < br / > Blockstone is a randomized phase 3 post exposure prevention study in which participants are family members of influenza patients The results showed that compared with the placebo group, the use of baloxavir marboxil after contact with infected family members could reduce the risk of influenza by 86% Only 1.9% of the family members who received prophylactic treatment of baloxavir marboxil were ill, while 13.6% of the family members who received placebo treatment were ill Baloxavir marboxil's current comprehensive clinical evidence shows that it has significant benefits in the prevention and treatment of influenza < br / > save the bald! The results of phase 2 clinical trial of modified JAK inhibitors are very good < br / > concert pharmaceuticals has published the results of phase 2 clinical trial of Jak1 / 2 inhibitor ctp-543, which is being developed to treat moderate to severe alopecia areata Alopecia areata is an autoimmune disease that causes hair to flake off The results of the phase 2 trial showed that more than 50% of patients treated with higher dose ctp-543 had significant remission compared with placebo < br / > ctp-543 is a drug for alopecia areata studied by concert company Ctp-543 is a deuterium modified form of ruxolitinib, a Jak1 / 2 inhibitor Around 2014, Yale University researchers found that a JAK inhibitor can treat multiple alopecia areata The JAK kinase family belongs to the cytoplasmic tyrosine kinase family, which has four subtypes and overlapping binding objects JAK kinases are thought to play an important role in inflammation because they involve the signaling of more than 50 cytokines and growth factors, many of which are involved in driving immune-mediated responses This kinase family inhibitor has been shown to be effective in the treatment of some inflammatory and autoimmune diseases Compared with placebo, ctp-543 can significantly alleviate the symptoms of more than 50% of patients after 24 weeks Compared with the two groups, the effect of 12 mg each time was much better than that of 8 mg each time: 78% of the patients receiving 12 mg and 58% of the patients receiving 8 mg, the symptoms were significantly relieved after 24 weeks The full results of this study will be presented at future medical conferences < br / > US $840 million in new immunotherapy! Novartis and IFM shake hands again < br / > IFM therapeutics, a biomedical company dedicated to developing innovative therapies targeting innate immune system, announced that its subsidiary IFM due has reached an R & D agreement with Novartis The two sides will work together to develop a series of innovative immunotherapies to inhibit the CGAs / sting signaling pathway and treat a variety of serious inflammatory and autoimmune diseases Previously, IFM therapeutics had reached a R & D cooperation with Novartis to develop anti-inflammatory therapy based on NLRP3 target < br / > IFM due has developed small molecule antagonists and inhibitors for the inflammatory response of congenital immune system abnormalities to solve a series of indications including rare, autoimmune, fibrotic and neurodegenerative diseases At present, the company has two preclinical projects under development, one is oral sting small molecule antagonists, which can prevent sting from stimulating the production of excessive interferon and other proinflammatory cytokines Clinical trials of the drug are expected to begin in 2021 Another project is to develop small molecule inhibitors of CGAs, aiming to block the nodes upstream of signal pathway < br / > In exercising their rights, shareholders of IFM due will be entitled to payments totalling up to $840 million < br / > develop PARP inhibitor radiotherapy! AstraZeneca, which works with Theragnostics < br / > to develop medical imaging tools and radiotherapy for a variety of cancers, announced that it has entered into a license agreement with AstraZeneca for intellectual property rights Theragnostics can develop specific radionuclide labeled PARP inhibitors in the field of diagnosis and obtain the option to develop specific radionuclide labeled PARP inhibitors in the field of treatment < br / > PARP inhibitor is an important anticancer therapy It can reduce the DNA repair function of tumor cells and enhance their sensitivity to DNA damage factors by inhibiting the activity of PARP, so as to improve the therapeutic effect of radiotherapy and chemotherapy At present, 4 kinds of PARP inhibitors have been approved by FDA < br / > Theragnostics' technology platform will develop molecular radiotherapy based on PARP inhibitors and use it in cancer imaging and treatment In this technique, the drug molecules of PARP inhibitors are modified with radioactive atoms to produce the radionuclide PARP inhibitors (rparpi) The technique can be used to image PARP in cancer patients, assist patients in diagnosis, or transport therapeutic radioisotopes to tumor cells This method not only enhances the potential to hit and kill tumor cells, but also avoids damaging healthy cells and causing related side effects < br / > rare lung diseases are welcome! The new medicine of Boehringer Ingelheim was approved by FDA < br / > the FDA of the United States announced that it approved the listing of ofev (nitedanib) developed by Boehringer Ingelheim company, which was used to delay the decline of lung function in adult patients with systemic sclerosis (scleroderma) related interstitial lung disease (SSC ILD) This is the first approved treatment for this rare lung disease < br / > Image Source: bringer Ingelheim official website < br / > scleroderma is a rare disease that causes the thickening of tissues (including lungs and other organs) all over the body and the formation of scar tissue Interstitial lung disease (ILD), the most common manifestation of scleroderma, is a disease that affects the lung stroma SSC ILD is a kind of progressive lung disease The lung function of patients is gradually decreased, which may be life-threatening ILD is the primary cause of death in patients with scleroderma Because of the gradual decline of lung function, the lungs of patients can not provide enough oxygen for the heart < br / > ofev has been approved by FDA for therapeutic use
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.